Zacks Investment Research
10 Aug 2026, 22:56 UTC · 11w ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Impact · against what's priced in
Orchestra BioMed Holdings (OBIO) faces negative pressure following a significant revenue miss and wider-than-expected quarterly losses. The steep decline in revenue compared to the previous year suggests deteriorating business performance.
- OBIO−0.50
No priced-in read yet





